How RWE can support drug development during COVID-19 and beyond
The COVID-19 pandemic introduced novel challenges for global biopharma organizations, as many...
The COVID-19 pandemic introduced novel challenges for global biopharma organizations, as many...
COVID-19 has heightened the need for an expanded understanding of clinical trial populations and...
Regulatory decision-making depends on evidence that reflects how medical products perform in real-world use, not only in controlled trials. For more than a decade, the Food and Drug Administration has relied on real-world data and real-world evidence...